Breast Cancer Clinical Trials in Indiana

46 recruiting studies across 1 city

Browse by City

All Trials in Indiana

Phase

Trial	Phase	Sponsor	Dist.
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer	N/A	SWOG Cancer Research Network	<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25	Phase 3	NRG Oncology	<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)	Phase 3	NRG Oncology	<1 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity	Phase 3	SWOG Cancer Research Network	<1 mi
Exercise in Metastatic Breast Cancer: EMBody	N/A	Indiana University	<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab	Phase 3	Alliance for Clinical Trials in Oncology	<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab	Phase 3	Alliance for Clinical Trials in Oncology	<1 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer	Phase 3	Canadian Cancer Trials Group	<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer	Phase 3	SWOG Cancer Research Network	<1 mi
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery	Phase 1	SURGE Therapeutics	<1 mi
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy	Phase 2	BioNTech SE	<1 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Phase 3	National Cancer Institute (NCI)	<1 mi
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer	Phase 1	Calibr, a division of Scripps Research	<1 mi
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)	Phase 3	Gilead Sciences	<1 mi
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.	Phase 1/2	RayzeBio, Inc.	<1 mi
NearWave Optical Molecular Monitoring	N/A	Indiana University	<1 mi
Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer	Phase 2	Abramson Cancer Center at Penn Medicine	<1 mi
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases	Phase 1/2	Colette Shen	<1 mi
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer	Phase 2	Mayo Clinic	<1 mi
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers	Phase 2	Kathy Miller	<1 mi
Study of 68Ga-R10602	Phase 1	Radionetics Oncology	<1 mi
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer	Phase 3	Relay Therapeutics, Inc.	<1 mi
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread	Phase 1/2	Boehringer Ingelheim	<1 mi
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer	Phase 3	Novartis Pharmaceuticals	<1 mi
ATEMPT 2.0: Adjuvant T-DM1 vs TH	Phase 2	Dana-Farber Cancer Institute	<1 mi
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer	Phase 2	Dana-Farber Cancer Institute	<1 mi
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	Phase 1	Relay Therapeutics, Inc.	<1 mi
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
HER2 Vaccine for Locally Advanced Breast Cancer	Phase 1	Pravin T.P Kaumaya	<1 mi
Study of LP-184 in Patients With Advanced Solid Tumors	Phase 1/2	Lantern Pharma Inc.	<1 mi
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer	Phase 3	AstraZeneca	<1 mi
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)	Phase 3	Eli Lilly and Company	<1 mi
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors	N/A	NRG Oncology	<1 mi
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer	Phase 1	Radionetics Oncology	<1 mi
Increasing Germline Genetic Testing for Patients With Cancer	N/A	Josh Peterson	<1 mi
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors	Phase 1/2	Hummingbird Bioscience	<1 mi
A Study of LY4175408 in Participants With Advanced Cancer	Phase 1	Eli Lilly and Company	<1 mi
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors	Phase 1	IDEAYA Biosciences	<1 mi
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/2	Volastra Therapeutics, Inc.	<1 mi
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab	Phase 1	AbbVie	<1 mi
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	Phase 1	Tizona Therapeutics, Inc	<1 mi
A Study of Sigvotatug Vedotin in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	Phase 1	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	<1 mi
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation	Phase 3	AstraZeneca	11 mi
Study of Oral MRT-2359 in Selected Cancer Patients	Phase 1/2	Monte Rosa Therapeutics, Inc	46 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.